

The image features a dark blue background with several glowing jellyfish. The Bricco logo is prominently displayed in the center. The word "Bricco" is written in a large, white, sans-serif font. To the right of the word is a stylized icon consisting of a central vertical bar with two horizontal bars extending from its top and bottom, and two more horizontal bars extending from its sides, forming a cross-like shape with rounded ends. The jellyfish in the background are translucent and emit a bright blue glow, with their tentacles visible.

Bricco

INTERIM REPORT Q1 2026

EARNINGS CALL

—
WEDNESDAY, APRIL 29, 2026

DISCLAIMER

You must read the following before continuing. The following applies to this document and the information provided in this presentation by BICO AB (publ) (the "Company") or any person on behalf of the Company and any other material distributed or statements made in connection with such presentation (the "Information"), and you are therefore advised to carefully read the statements below before reading, accessing or making any other use of the Information. In accessing the Information, you agree to be bound by the following terms and conditions.

The Information does not constitute or form part of, and should not be construed as, an offer of invitation to subscribe for, underwrite or otherwise acquire, any securities of the Company or a successor entity or any existing or future subsidiary or affiliate of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of the Company or any of such subsidiaries or affiliates nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Specifically, this presentation does not constitute a "prospectus" within the meaning of the U.S. Securities Act of 1933, as amended.

The Information may not be reproduced, redistributed, published or passed on to any other person, directly or indirectly, in whole or in part, for any purpose. The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information is not

for publication, release or distribution in the United States, the United Kingdom, Australia, Canada or Japan, or any other jurisdiction in which the distribution or release would be unlawful.

All of the Information herein has been prepared by the Company solely for use in this presentation. The Information contained in this presentation has not been independently verified. No representation, warranty or undertaking, expressed or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the Information or the opinions contained herein. The Information contained in this presentation should be considered in the context of the circumstances prevailing at that time and has not been, and will not be, updated to reflect material developments which may occur after the date of the presentation. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes.

This presentation may contain certain forward-looking statements and forecasts which relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on the Company's operations, financial position and earnings. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in a forward-looking statement or

affect the extent to which a particular projection is realized. Factors that could cause these differences include, but are not limited to, implementation of the Company's strategy and its ability to further grow, risks associated with the development and of the Company's products, ongoing research and development, the ability to commercialize the Company's products, technology changes and new products in the Company's potential market and industry, the ability to develop new products, the impact of competition, changes in general economy and industry conditions and legislative, regulatory and political factors. While the Company always intends to express its best judgment when making statements about what it believes will occur in the future, and although the Company bases these statements on assumptions that it believes to be reasonable when made, these forward-looking statements are not a guarantee of its performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of the Company's control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this presentation are made only as of the date hereof. The Company does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments.



Earnings Call Agenda



Maria Forss
President & CEO



Ewa Linsäter
CFO

- » Summary Q1 2026
- » Group Financial Performance
- » Continuous Product Innovation
- » Concluding Remarks
- » Q&A



Q1 2026

330

NET SALES
SEK m

11

ORGANIC SALES
GROWTH
%


-11

ADJUSTED EBITDA
SEK m

47


OPERATING CASH FLOW
SEK m

Q1 2025 - Q1 2026
Net sales and adjusted EBITDA margin




BICO's Portfolio Supports with Workflows Along Drug and Diagnostic Development to Automate Labs

BICO's current strengths and technologies are largely grouped into three fields



The Global Challenge

Long and costly clinical stages combined with low success rate comprise a global challenge for the drug development industry



BICO Lab Automation Provides the Execution & Validation layer converting AI hypotheses into proven experimental evidence



- More AI-driven candidates mean **more experiments, not fewer**
- **AI acceleration shifts the bottleneck to the wet lab**
- The wet lab becomes even more mission-critical; **the indispensable infrastructure that makes AI-powered biotech work.**

Roadmap for AI-Powered Lab Automation with Green Button Go



AVAILABLE TODAY

Assistive AI in Platform

Our AI Platform brings natural-language workflow creation and troubleshooting to Green Button Go®, making automation accessible to every scientist.



NEXT-GEN ROADMAP

Crescendo: Scale & Orchestration

Developing GBG to scale experimental throughput while preserving human-in-the-loop oversight and data integrity end-to-end.



DURABLE MOAT

Reliability · Integrity · Compliance


As AI-driven experiments surge, trusted execution becomes indispensable infrastructure, cementing platform lock-in at the core of biotech R&D.

- With the Green Button Go footprint, **our models leverage hundreds of installations and years of operational data**
- Biosero's Green Button Go enables AI-powered automation in the web lab **to ease the bottleneck**




Purpose

BICO exists so therapies reach humanity sooner.



Vision

To enable life-science labs to accelerate the discoveries that change lives.



Mission

BICO leverages a global portfolio of pioneering brands fusing automation, intelligence, and data to unlock scientific discovery at scale.

Trust


Focus

Collaboration

Grit

The Results of Automation Have Never Been More Important

REDUCING THE COST AND TIMELINE TO MARKETABLE DISCOVERIES IS IMPERATIVE



2024 productivity metrics from a major pharmaceutical company leveraging Green Button Go Orchestrator.



BICO Leads the way in Solving the Challenges in Life Science with Speed, Accuracy, and Efficiency

Speed

- Reducing the time to find optimal candidates for treatment therapies
- Driving forward a personalized approach in treatment


Accuracy

- Enabling the development of physiologically relevant models
- Enhancing reproducibility through automated processes that reduce variability in experimental outcomes

Efficiency

- Maximize productivity of automated laboratory equipment and scientists





Summary of Q1 2026



Summary | Q1 2026

NET SALES
SEK 330m

ADJUSTED EBITDA
SEK -11m

CASH FLOW FROM
OPERATING ACTIVITIES
SEK 47 m

ORGANIC SALES GROWTH
11%

ADJUSTED
EBITDA MARGIN
-3.4%

NWC/LTM SALES
7%

All numbers in this presentation refer to continuing operations if not otherwise stated.
MatTek and Visikol have been classified as discontinued operations with retroactive effect.






Group Financial Performance




Sales Development (SEKm)



- Sales SEK 330m with organic growth of 11 %
- Growth mainly driven by desktop instruments
- The difference between sales growth and organic sales growth - mainly explained by a weaker US dollar against the Swedish Crona



Adjusted EBITDA (SEKm) and Margin (%)



- Adjusted EBITDA SEK –11.4m corresponding to a margin of -3.4 percent
- Restructring costs of SEK 52.5m whereof SEK 30.2m affected EBITDA
- Annualised savings of ca SEK 30m from restructuring program






Cash Flow and Financial Position

- **Cash flow from operating activities, SEK 47m**
 - includes impact from changes in working capital of SEK 79m
- **Total cash flow during Q1 was SEK -547m**
 - Issued secured senior bonds of EUR 40m
 - Previous existing bonds, originally issued in 2021, of SEK 1,008m was settled upon maturity
 - Net proceeds from divestment of Finnish property, SEK 32m
- **Cash reserves by end of the quarter SEK 744**



Development in Net Working Capital between Q1 2025 and Q1 2026*





BICO Issued Senior Secured Bonds

- Total nominal of EUR 40 million
- Tenor of four years
- The bonds were placed with a consortium of Swedish institutional investors
- Supporting further growth and capture market recovery while navigating ongoing macroeconomic uncertainty






Continuous Product Innovation



R&D Pipeline & Roadmap



AI-Powered VCD & Cell Counting on the UP.SIGHT

CYTENA's UP.SIGHT 2nd GEN continues its evolution from a single-cell dispenser into an all-in-one CLD analytical instrument, consolidating fragmented steps in CLD workflows.

10x faster

time-to-result vs. sequential VCD on the industry standard Vi-CELL BLU.

€20–30k / year

estimated savings per mid-size CLD lab (consumables + hands-on time)



WHY IT MATTERS FOR CLD CUSTOMERS

PERFORMANCE

AI-based cell detection and count

The use of AI increase the precision and robustness of measurements, effectively cutting the need for multiple dilutions and replicates per sample — saving ~150,000 pipette tips/year plus dilution plates and reagents in a representative mid-size CLD lab.

SPEED

Up to 384 samples in parallel

Legacy VCD instruments analyze one sample at a time — autoloaders only queue them. UP.SIGHT delivers VCD data for a full clone panel in minutes, enabling same-day decisions instead of overnight or full-day acquisition.

CONVENIENCE

All the data in one place

Cell count and VCD values are accessible directly in C.STUDIO, the ultimate CLD management software that centralizes all clones' intelligence in a single place to break data silos in CLD and streamline data-driven decision.

Launching spring 2026

AUTOMATED BEAD-BASED CLEAN-UP

G.PURE GEN 2


The G.PURE GEN 2 from CYTENA, automates DNA purification, delivering rapid, reproducible, plastic tip-free sample cleanup for efficient NGS library preparation workflows.



AUTOMATED NGS WORKSTATION

G.STATION GEN 2

The G.STATION GEN 2 from DISPENDIX, automates the NGS library preparation workflow, enabling the scalable, cost-efficient production of consistent sequencing-ready libraries for genomics and drug discovery applications.



Roadmap for AI-Powered Lab Automation with Green Button Go



AVAILABLE TODAY

Assistive AI in Platform

Our AI Platform brings natural-language workflow creation and troubleshooting to Green Button Go®, making automation accessible to every scientist.



NEXT-GEN ROADMAP

Crescendo: Scale & Orchestration


Developing GBG to scale experimental throughput while preserving human-in-the-loop oversight and data integrity end-to-end.



DURABLE MOAT

Reliability · Integrity · Compliance

As AI-driven experiments surge, trusted execution becomes indispensable infrastructure, cementing platform lock-in at the core of biotech R&D.

The background features several glowing jellyfish in shades of cyan and blue against a dark, almost black, background. The jellyfish are illuminated from within, creating a soft, ethereal glow. Some jellyfish are in sharp focus, while others are blurred in the foreground and background, creating a sense of depth. The overall aesthetic is clean, modern, and scientific.

Concluding Remarks



BICO Vision and Strategic Agenda

Vision

TO ENABLE LIFE SCIENCE LABS
TO ACCELERATE THE DISCOVERIES THAT CHANGE LIVES

Mission

BICO leverages a global portfolio of pioneering brands
fusing automation, intelligence, and data to unlock scientific discovery at scale

Strategic
focus
areas

Enable end-to-end
lab automation &
scientific workflow
solutions



Further develop
integrated data,
AI and software
solutions



Ensure **regulatory**
compliance
readiness



Expand strategic
partnerships



Increase
recurring revenue



Values

Trust

Focus

Collaboration

Grit

Impact

Speed and quality through
automated technology

Efficiency in drug
development

Tools to accelerate
personalized medicine

Alternatives to
animal testing

Financial
Targets

Double-digit organic growth
in constant currency

EBITDA margin less capitalized
development cost > 10%

Net Debt to EBITDA < 3.0x



Focus Areas 2026 for Profitable Growth

1

Commercial Execution

2

R&D Pipeline Execution

3

Financial Discipline





Q&A



BrCO 

Financial Calendar



MAY 7, 2026
Annual General Meeting 2026



AUGUST 19, 2026
Q2 Report 2026



NOVEMBER 11, 2026
Q3 Report 2026



FEBRUARY 17, 2027
Year-end Report 2026

Contact

**MARIA FORSS, CEO AND PRESIDENT
BICO GROUP AB**

Phone: EA Elisabeth Lindell, +46 761 73 40 59
E-mail: mf@bico.com

**EWA LINSÄTER, CFO
BICO GROUP AB**

Phone: +46 766 333 233
E-mail: ewa.linsater@bico.com

BICO strives towards the vision to enable life-science labs to accelerate the discoveries that change lives.

We do this by leveraging a global portfolio of pioneering brands fusing automation, intelligence, and data to unlock scientific discovery at scale.



Brico 